Literature DB >> 14651959

Divergent roles of GSK3 and CDK5 in APP processing.

John Ryder1, Yuan Su, Feng Liu, Baolin Li, Yan Zhou, Binhui Ni.   

Abstract

Glycogen synthase kinase-3 (GSK3) and cyclin-dependent kinase 5 (CDK5) are related serine/threonine kinases that have been well studied for their role in tau hyperphosphorylation, however, little is known about their significance in APP processing. Here we report that GSK3 and CDK5 are involved in APP processing in a divergent manner. Specific inhibition of cellular GSK3 by lithium or GSK3beta antisense elicits a reduction in Abeta. Conversely, negative modulation of cellular CDK5 activity by CDK5 inhibitor, roscovitine, or CDK5 antisense stimulates Abeta production. Neither GSK3 nor CDK5 inhibition by these means significantly affected cellular APP levels or APP maturation. Moreover, oral administration of lithium significantly reduces Abeta production whereas direct ICV administration of roscovitine augmented Abeta production in the brains of PDAPP (APP(V717F)) mice. Our data support a function for both GSK3 and CDK5 in APP processing, further implicating these two kinases in the pathogenesis of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14651959     DOI: 10.1016/j.bbrc.2003.11.014

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  39 in total

Review 1.  Synapses and Alzheimer's disease.

Authors:  Morgan Sheng; Bernardo L Sabatini; Thomas C Südhof
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-05-01       Impact factor: 10.005

2.  Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease.

Authors:  David E Hurtado; Laura Molina-Porcel; Jenna C Carroll; Caryn Macdonald; Awo K Aboagye; John Q Trojanowski; Virginia M-Y Lee
Journal:  J Neurosci       Date:  2012-05-23       Impact factor: 6.167

3.  The Effects of Astilbin on Cognitive Impairments in a Transgenic Mouse Model of Alzheimer's Disease.

Authors:  Dongmei Wang; Sanqiang Li; Jing Chen; Ling Liu; Xiaoying Zhu
Journal:  Cell Mol Neurobiol       Date:  2016-07-19       Impact factor: 5.046

Review 4.  GSK3beta: role in therapeutic landscape and development of modulators.

Authors:  S Phukan; V S Babu; A Kannoji; R Hariharan; V N Balaji
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

Review 5.  Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics.

Authors:  Richard S Jope; Christopher J Yuskaitis; Eléonore Beurel
Journal:  Neurochem Res       Date:  2006-08-30       Impact factor: 3.996

6.  The amyloid-beta precursor protein is phosphorylated via distinct pathways during differentiation, mitosis, stress, and degeneration.

Authors:  Zoia Muresan; Virgil Muresan
Journal:  Mol Biol Cell       Date:  2007-07-18       Impact factor: 4.138

7.  In AbetaPP-overexpressing cultured human muscle fibers proteasome inhibition enhances phosphorylation of AbetaPP751 and GSK3beta activation: effects mitigated by lithium and apparently relevant to sporadic inclusion-body myositis.

Authors:  Chiara Terracciano; Anna Nogalska; W King Engel; Valerie Askanas
Journal:  J Neurochem       Date:  2009-10-29       Impact factor: 5.372

Review 8.  Supraphysiologic-dose anabolic-androgenic steroid use: A risk factor for dementia?

Authors:  Marc J Kaufman; Gen Kanayama; James I Hudson; Harrison G Pope
Journal:  Neurosci Biobehav Rev       Date:  2019-02-25       Impact factor: 8.989

9.  Loss of Hsp110 leads to age-dependent tau hyperphosphorylation and early accumulation of insoluble amyloid beta.

Authors:  Binnur Eroglu; Demetrius Moskophidis; Nahid F Mivechi
Journal:  Mol Cell Biol       Date:  2010-08-02       Impact factor: 4.272

10.  GSK3beta regulates differentiation and growth arrest in glioblastoma.

Authors:  Serdar Korur; Roland M Huber; Balasubramanian Sivasankaran; Michael Petrich; Pier Morin; Brian A Hemmings; Adrian Merlo; Maria Maddalena Lino
Journal:  PLoS One       Date:  2009-10-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.